Molecular and immunological dissection of diffuse large b cell lymphoma: cd5+, and cd5− with cd10+ groups may constitute clinically relevant subtypes

Molecular and immunological dissection of diffuse large b cell lymphoma: cd5+, and cd5− with cd10+ groups may constitute clinically relevant subtypes

Play all audios:

Loading...

ABSTRACT Diffuse large B cell lymphoma (DLBL) constitutes the greatest percentage of adult non-Hodgkin’s lymphomas and represents a diverse spectrum of lymphoid neoplasms. Clinicopathologic, phenotypic and genotypic findings were correlated and compared for 63 DLBL cases to investigate whether they represent clinically relevant subtypes. They were all cyclin D1 negative and were phenotypically divided into three groups, ie group I (CD5+ type, _n_ = 11), group II (CD5− CD10+ type, _n_ = 19), and group III (CD5− CD10− type, _n_ = 33). Data were correlated by observing the respective gene rearrangement and expression of _BCL2_ and _BCL6_. In clinical aspects, the group I cases demonstrated a significantly inferior survival than those of the other two groups (log-rank test, _P_ = 0.016). Although rearrangement of _BCL2_ and _BCL6_ did not show any inclination to a specific subgroup, the immunohistochemical detection of BCL2 was less frequent, at a statistically significant level (_P_ = 0.011), in group II (50%) than in group I (82%) and III (82%) cases. This appears to confirm the unique aspect of the CD5− CD10+ type DLBL, indicating a certain relationship with the normal germinal center cells which usually lack BCL2 expression. The BCL6 protein expression was detected in most of the present DLBL cases (92%) irrespective of this grouping. These data suggest that the phenotypic delineation by the detection of CD5 and CD10 will improve our understanding of DLBL and be helpful in a future subgrouping of DLBL. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BCL2 SUPER-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA: A DISTINCT SUBGROUP ASSOCIATED WITH POOR PROGNOSIS Article 11 November 2021 CLINICAL RELEVANCE OF MYC/BCL2 EXPRESSION AND CELL OF ORIGIN IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH AUTOLOGOUS TRANSPLANT Article 18 May 2023 CLINICAL IMPLICATIONS OF CSF-CTDNA POSITIVITY IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA Article 15 May 2024 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Japan S Harada, R Suzuki & M Seto * Second Department of Internal Medicine, Nagoya City University School of Medicine, Japan S Harada & R Ueda * Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, Japan K Uehira, Y Kagami, M Ogura & Y Morishima * Department of Pathology and Clinical Laboratories, Aichi Cancer Center Hospital, Japan Y Yatabe & S Nakamura * Department of Internal Medicine, Okazaki Municipal Hospital, Japan H Suzuki * Department of Internal Medicine, Aichi Prefectural Hospital, Japan A Oyama * Department of Internal Medicine, Japanese Red Cross, Nagoya First Hospital, Japan Y Kodera Authors * S Harada View author publications You can also search for this author inPubMed Google Scholar * R Suzuki View author publications You can also search for this author inPubMed Google Scholar * K Uehira View author publications You can also search for this author inPubMed Google Scholar * Y Yatabe View author publications You can also search for this author inPubMed Google Scholar * Y Kagami View author publications You can also search for this author inPubMed Google Scholar * M Ogura View author publications You can also search for this author inPubMed Google Scholar * H Suzuki View author publications You can also search for this author inPubMed Google Scholar * A Oyama View author publications You can also search for this author inPubMed Google Scholar * Y Kodera View author publications You can also search for this author inPubMed Google Scholar * R Ueda View author publications You can also search for this author inPubMed Google Scholar * Y Morishima View author publications You can also search for this author inPubMed Google Scholar * S Nakamura View author publications You can also search for this author inPubMed Google Scholar * M Seto View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Harada, S., Suzuki, R., Uehira, K. _et al._ Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes. _Leukemia_ 13, 1441–1447 (1999). https://doi.org/10.1038/sj.leu.2401487 Download citation * Received: 08 March 1999 * Accepted: 11 May 1999 * Published: 09 September 1999 * Issue Date: 01 September 1999 * DOI: https://doi.org/10.1038/sj.leu.2401487 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * diffuse large B cell lymphoma * CD5 * CD10 * _BCL2_ * _BCL6_

ABSTRACT Diffuse large B cell lymphoma (DLBL) constitutes the greatest percentage of adult non-Hodgkin’s lymphomas and represents a diverse spectrum of lymphoid neoplasms. Clinicopathologic,


phenotypic and genotypic findings were correlated and compared for 63 DLBL cases to investigate whether they represent clinically relevant subtypes. They were all cyclin D1 negative and


were phenotypically divided into three groups, ie group I (CD5+ type, _n_ = 11), group II (CD5− CD10+ type, _n_ = 19), and group III (CD5− CD10− type, _n_ = 33). Data were correlated by


observing the respective gene rearrangement and expression of _BCL2_ and _BCL6_. In clinical aspects, the group I cases demonstrated a significantly inferior survival than those of the other


two groups (log-rank test, _P_ = 0.016). Although rearrangement of _BCL2_ and _BCL6_ did not show any inclination to a specific subgroup, the immunohistochemical detection of BCL2 was less


frequent, at a statistically significant level (_P_ = 0.011), in group II (50%) than in group I (82%) and III (82%) cases. This appears to confirm the unique aspect of the CD5− CD10+ type


DLBL, indicating a certain relationship with the normal germinal center cells which usually lack BCL2 expression. The BCL6 protein expression was detected in most of the present DLBL cases


(92%) irrespective of this grouping. These data suggest that the phenotypic delineation by the detection of CD5 and CD10 will improve our understanding of DLBL and be helpful in a future


subgrouping of DLBL. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution


Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full


article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *


Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS BCL2 SUPER-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA: A DISTINCT SUBGROUP ASSOCIATED WITH POOR PROGNOSIS Article 11 November


2021 CLINICAL RELEVANCE OF MYC/BCL2 EXPRESSION AND CELL OF ORIGIN IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH AUTOLOGOUS TRANSPLANT Article 18 May 2023 CLINICAL IMPLICATIONS


OF CSF-CTDNA POSITIVITY IN NEWLY DIAGNOSED DIFFUSE LARGE B CELL LYMPHOMA Article 15 May 2024 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Laboratory of Chemotherapy, Aichi Cancer Center


Research Institute, Japan S Harada, R Suzuki & M Seto * Second Department of Internal Medicine, Nagoya City University School of Medicine, Japan S Harada & R Ueda * Department of


Hematology and Chemotherapy, Aichi Cancer Center Hospital, Japan K Uehira, Y Kagami, M Ogura & Y Morishima * Department of Pathology and Clinical Laboratories, Aichi Cancer Center


Hospital, Japan Y Yatabe & S Nakamura * Department of Internal Medicine, Okazaki Municipal Hospital, Japan H Suzuki * Department of Internal Medicine, Aichi Prefectural Hospital, Japan A


Oyama * Department of Internal Medicine, Japanese Red Cross, Nagoya First Hospital, Japan Y Kodera Authors * S Harada View author publications You can also search for this author inPubMed 


Google Scholar * R Suzuki View author publications You can also search for this author inPubMed Google Scholar * K Uehira View author publications You can also search for this author


inPubMed Google Scholar * Y Yatabe View author publications You can also search for this author inPubMed Google Scholar * Y Kagami View author publications You can also search for this


author inPubMed Google Scholar * M Ogura View author publications You can also search for this author inPubMed Google Scholar * H Suzuki View author publications You can also search for this


author inPubMed Google Scholar * A Oyama View author publications You can also search for this author inPubMed Google Scholar * Y Kodera View author publications You can also search for


this author inPubMed Google Scholar * R Ueda View author publications You can also search for this author inPubMed Google Scholar * Y Morishima View author publications You can also search


for this author inPubMed Google Scholar * S Nakamura View author publications You can also search for this author inPubMed Google Scholar * M Seto View author publications You can also


search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Harada, S., Suzuki, R., Uehira, K. _et al._ Molecular and


immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes. _Leukemia_ 13, 1441–1447 (1999).


https://doi.org/10.1038/sj.leu.2401487 Download citation * Received: 08 March 1999 * Accepted: 11 May 1999 * Published: 09 September 1999 * Issue Date: 01 September 1999 * DOI:


https://doi.org/10.1038/sj.leu.2401487 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not


currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * diffuse large B cell lymphoma * CD5 * CD10 * _BCL2_ *


_BCL6_